Skip to main content

Committed to Doing our Part: 2022 Corporate Sustainability Report Highlights

May 3, 2023

  1. Committed to Doing our Part: 2022 Corporate Sustainability Report Highlights

    Last week, we were thrilled to publish the PTC 2022 Corporate Sustainability Report. “Committed to doing our part” is a comprehensive look at our science, support for rare disease patient communities and access to care, our strengths-based learning culture, global equality, diversity and inclusion, efforts to help the environment, and much more. As a growing…

  2. PTC Planting Trees for the Future

    Last week in Switzerland, PTC colleagues teamed up to plant trees in an effort to make an environmental impact. In partnership with OneTree Planted and Almighty Tree this year, 100 Oak trees were planted to help combat climate change and prevent biodiversity loss for generations to come. Tree planting is critical to reforestation and afforestation…

  3. PTC Issues 2021 Corporate Sustainability Report

    We recently issued our 2021 Corporate Sustainability Report (PDF), outlining our efforts and impact in key areas throughout 2021. PTC’s commitment to corporate responsibility focuses on five areas: our patients, our people, our community, our values, and our environment. As a growing, global company with a footprint in more than 50 countries, our mission remains…

  4. Maintaining a Healthy World: PTC’s Environmental Sustainability Commitment

    This year’s theme for Earth Day is Invest in Our Planet, emphasizing the importance of protecting and preserving in the health of the Earth – for ourselves and our families. We understand the impact people have on the environment, which is why we’ve always ensured we are compliant with environmental requirements and regulations. We encourage…

  5. Webinar: Rare Paediatric Neurological Diseases: A Focus on Europe

    Wednesday, 23 March 2022 – 14:00 – 15:00 (CET) PTC Therapeutics invites you to participate in a multi-stakeholder webinar to present the findings of the Economist Impact* report ‘Rare paediatric neurological diseases: A focus on Europe’ and discuss how policymakers, industry, healthcare providers and patients can collaborate to improve care and outcomes. Rare paediatric neurological…

  6. PTC in 2021: A Year of Expansion

    For PTC, 2021 was about expansion – not just literally, as we grew our global reach and added team members, but what we can do for patients, too, through our awareness efforts and continued dedication to scientific innovation. Expansion by definition is the act of becoming larger or more extensive. And in fact, we had so much good news in 2021, it was hard for us to pick the highlights to include…

  7. Our Commitment to the Rare Disease Community

    PTC was founded in 1998 by a scientist with a desire to serve patients with rare diseases and unmet medical needs. Over the course of our history, we have grown to a team of more than a thousand employees and developed new innovative therapies. However, we’ve always maintained our foundational commitment to our patients and…

  8. Expanding the Rare Disease Patient Voice at the BIO Patient & Health Advocacy Summit

    For the past three years, PTC has joined patient advocacy organizations, academia, regulators, the life sciences industry, and other stakeholders from around the United States as a sponsor of the BIO Patient & Health Advocacy Summit. This two-day inspirational event offers PTC employees the chance to join their solution-focused peers and share challenges, ideas, and…

  9. Enrolling Your Child in a Clinical Trial – Get the Basics

    Key Takeaways • PTC clinical trials are regulated and reviewed by the FDA in the United States, and by local regulatory authorities, ethics committees, and institutional review boards in respective markets • Most patients in PTC trials see an independent doctor for evaluation before enrolling • PTC trial staff and researchers monitor individual patient data…

  10. STRIVE: Structuring the Clinic for Basic Care at ASCADIM

    ASCADIM provides physical, psychological, and social care to people with muscular dystrophies in Southern Brazil. The organization was created based on insights from parents on the despair they felt following diagnosis and their desire for more and trusted information. Via ASCADIM, patients and their families can access vital support, guidance, and free physical therapy –…